R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.
Cyclin K (E7F4N) Rabbit mAb #19472
Filter:
- WB
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 79 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
Cyclin K (E7F4N) Rabbit mAb recognizes endogenous levels of total cyclin K protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala15 of human cyclin K protein.
Background
Cyclin K is a positive regulator of transcriptional cyclin-dependent kinases (CDKs) CDK12 and CDK13. The cyclin K/CDK12 complex regulates the formation of the pre-replicative complex during G1 phase of the cell cycle (1), as well as the expression of key proteins in the DNA Damage Response (DDR) (2). Regulation of DDR-related gene expression involves cyclin K interaction with the histone methyltransferase SETD1A (3).
Due to its importance in maintaining genome stability through regulation of the DDR, the cyclin K/CDK12 complex is an emerging therapeutic target in human cancer (4,5). Targeted protein degradation via molecular glues and PROTACs have been employed to specifically degrade cyclin K/CDK12 as a means of targeting the DDR in human cancer (6-9).
Due to its importance in maintaining genome stability through regulation of the DDR, the cyclin K/CDK12 complex is an emerging therapeutic target in human cancer (4,5). Targeted protein degradation via molecular glues and PROTACs have been employed to specifically degrade cyclin K/CDK12 as a means of targeting the DDR in human cancer (6-9).
- Lei, T. et al. (2018) Nat Commun 9, 1876.
- Blazek, D. (2012) Cell Cycle 11, 1049-50.
- Hoshii, T. et al. (2018) Cell 172, 1007-1021.e17.
- Emadi, F. et al. (2020) Drug Discov Today 25, 2257-2267.
- Liu, H. et al. (2021) Cancer Res 81, 18-26.
- Lv, L. et al. (2020) Elife 9, e59994. doi: 10.7554/eLife.59994.
- Sun, R. et al. (2022) Proc Natl Acad Sci USA 119, e2205509119.
- Niu, T. et al. (2022) Eur J Med Chem 228, 114012.
- Sano, O. et al. (2023) Biochem Biophys Res Commun 676, 6-12.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.